Triveram Drug Interactions

Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see Contraindications, Precautions and Pharmacology: Pharmacodynamics under Actions).
No drug interaction studies have been conducted with Triveram and other drugs, although studies have been conducted with atorvastatin, perindopril and amlodipine separately. The results of these studies are provided as follows.
Drugs inducing hyperkalaemia: Some drugs or therapeutic classes may increase the occurrence of hyperkalaemia: aliskiren, potassium salts, potassium-sparing diuretics, ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents such as ciclosporine or tacrolimus, trimethoprim. The combination of these drugs increases the risk of hyperkalaemia.
Concomitant use contraindicated (see Contraindications): See Table 3.

Click on icon to see table/diagram/image

Concomitant use not recommended (see Precautions): See Table 4.

Click on icon to see table/diagram/image

Concomitant use which requires special care: See Table 5.

Click on icon to see table/diagram/image

Concomitant use to be taken into consideration: See Tables 6, 7 and 8.

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image